Gang Mm Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gang Mm Xiao has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kangze Wu
Department of Hepatobiliary Surgery, Shaoxing People’s Hospital, Shaoxing, China
1 shared publication - Liying Bsc Qian
Department of Hepatobiliary Surgery, Shaoxing People’s Hospital, Shaoxing, People’s Republic of China
1 shared publication - Zhihong Shen
Department of Hepatobiliary Surgery, Shaoxing People’s Hospital
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (25) , e42973
Surgical resection of vascular-invasive late-stage hepatocellular carcinoma following transarterial chemoembolization combined with lenvatinib and tislelizumab: Two case reports and literature review
Rationale: Hepatocellular carcinoma (HCC) with hepatic vein invasion poses significant treatment challenges and is associated with poor prognosis. Recent studies suggest that a combination of transarterial chemoembolization (TACE), targeted therapy, and immunotherapy may downstage advanced tumors, making surgical resection possible. Patient concerns: A 61-year-old female presented with a 3.7 × 3.1 cm hepatic mass invading the hepatic veins. A 75-year-old male exhibited a 6.7 × 5.1 cm liver tumor involving the right hepatic vein. Diagnoses: Both patients were diagnosed with advanced HCC with vascular invasion, confirmed by contrast-enhanced imaging and elevated alpha-fetoprotein (AFP) levels. Interventions: In case 1, the patient received 2 rounds of TACE and 3 cycles of lenvatinib plus tislelizumab. In case 2, the patient underwent 1 TACE session and 2 cycles of the same combination therapy. Both cases showed significant tumor shrinkage, allowing subsequent R0 surgical resection. Outcomes: Pathological evaluation following surgery revealed a major pathological response in both patients. Postoperative recovery was uneventful, and both patients remained disease-free during follow-up. Lessons: The combination of TACE, lenvatinib, and tislelizumab may offer an effective multimodal strategy for converting unresectable HCC with vascular invasion into resectable disease, potentially improving long-term outcomes.
- 20 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (25) , e42973
Open AccessSurgical resection of vascular-invasive late-stage hepatocellular carcinoma following transarterial chemoembolization combined with lenvatinib and tislelizumab: Two case reports and literature review
Rationale: Hepatocellular carcinoma (HCC) with hepatic vein invasion poses significant treatment challenges and is associated with poor prognosis. Recent studies suggest that a combination of transarterial chemoembolization (TACE), targeted therapy, and immunotherapy may downstage advanced tumors, making surgical resection possible. Patient concerns: A 61-year-old female presented with a 3.7 × 3.1 cm hepatic mass invading the hepatic veins. A 75-year-old male exhibited a 6.7 × 5.1 cm liver tumor involving the right hepatic vein. Diagnoses: Both patients were diagnosed with advanced HCC with vascular invasion, confirmed by contrast-enhanced imaging and elevated alpha-fetoprotein (AFP) levels. Interventions: In case 1, the patient received 2 rounds of TACE and 3 cycles of lenvatinib plus tislelizumab. In case 2, the patient underwent 1 TACE session and 2 cycles of the same combination therapy. Both cases showed significant tumor shrinkage, allowing subsequent R0 surgical resection. Outcomes: Pathological evaluation following surgery revealed a major pathological response in both patients. Postoperative recovery was uneventful, and both patients remained disease-free during follow-up. Lessons: The combination of TACE, lenvatinib, and tislelizumab may offer an effective multimodal strategy for converting unresectable HCC with vascular invasion into resectable disease, potentially improving long-term outcomes.